Gubra Investor Relations

Gubra

Investor Relations

Gubra Investor R&D Event October 27th, 2026 in London

Gubra Investor R&D Event October 27th, 2026 in London!

On 27 October 2026, Gubra hosted its Investor R&D Event in London, presenting its strategy and ambitions toward 2030, including plans to expand its clinical-stage pipeline and accelerate long-term value creation across Biotech, Ventures, and CRO.

Presentation (PDF)

Press release

Stock details

More stock info

Latest result

All Financial Reports

Contact Investor Relations

Kristian Borbos

Chief Financial Officer (CFO)

[email protected]

+45 3080 8035

Adam Lange

Head of Investor Relations

[email protected]

+45 6646 1589

Latest news

All News & Announcements

Oct 27, 2026

Gubra outlines 2030 strategy to scale innovation and expand its clinical-stage pipeline

Oct 21, 2026

REMINDER: Gubra Investor R&D Event on October 27, 2026

Sep 30, 2026

Gubra’s partner AbbVie presents detailed Phase 1 data for ABBV-295, a long-acting amylin analog, demonstrating favorable tolerability and pharmacokinetic profile at EASD 2026

Upcoming Events

Events & Financial Calendar

06/11/2026

Trading statement Q3-2026

15/11/2026

19/10/2026

Jefferies Global Healthcare Conference

London

13/01/2027

SEB Nordic Seminar 2027

Copenhagen

11/01/2027

14/01/2027

J.P. Morgan Healthcare Conference 2027

San Francisco

03/03/2027

Annual Report 2026

Past Events

27/10/2026

Gubra Investor R&D Event 2026

London

Watch recorded webcast
Download Presentation

14/09/2026

16/09/2026

Morgan Stanley 24th Annual Global Healthcare Conference

New York City

Link for fireside chat

02/09/2026

17th Annual Pareto Securities’ Healthcare Conference

Stockholm

Subscribe for

Press releases and reports

Follow Gubra

Article of Association

Audit Committee Charter

Anti-bribery and Corruption Policy

Code of Conduct

Diversity Policy

ESG Policy

Investor Relation Policy

Remuneration and Nomination Charter

Remuneration Policy

Scientific & Technology Committee Charter

Tax Policy

Whistleblower Policy

Corporate governance statement 2023

Corporate governance statement 2024

Corporate governance statement 2025